The National Institute for Health and Care Excellence

Hidden spine fractures could be spotted earlier after NICE recommendation

NICE is recommending that quick spine checks are added to routine bone scans to help spot hidden fractures earlier and prevent serious complications. Around 70% of spine fractures caused by ...
National Institute for Health and Care Excellence

Published guidance, NICE advice and quality standards

Dostarlimab with platinum-containing chemotherapy for treating primary advanced or recurrent endometrial cancer with microsatellite stability or mismatch repair proficiency TA1117 16 December 2025 16 ...
National Institute for Health and Care Excellence

Published guidance, NICE advice and quality standards

Dostarlimab with platinum-containing chemotherapy for treating primary advanced or recurrent endometrial cancer with microsatellite stability or mismatch repair proficiency TA1117 16 December 2025 16 ...
National Institute for Health and Care Excellence

Pressure ulcer prevention: pressure ulcer risk assessment and prevention, including the use of pressure-relieving devices (beds, mattresses and overlays) for the prevention of ...

Pressure ulcer prevention: pressure ulcer risk assessment and prevention, including the use of pressure-relieving devices (beds, mattresses and overlays) for the prevention of pressure ulcers in ...
National Institute for Health and Care Excellence

Pembrolizumab plus chemotherapy with or without bevacizumab for persistent, recurrent or metastatic cervical cancer

Guidance Standards and indicators Clinical Knowledge Summaries (CKS) British National Formulary (BNF) British National Formulary for Children (BNFC) Life sciences Library and knowledge services What ...
National Institute for Health and Care Excellence

Secukinumab for treating moderate to severe plaque psoriasis in children and young people

Evidence-based recommendations on secukinumab (Cosentyx) for moderate to severe plaque psoriasis in children and young people aged 6 to 17 years. Next review: This guidance will be reviewed if there ...
National Institute for Health and Care Excellence

Hybrid closed loop systems for managing blood glucose levels in type 1 diabetes

Access to hybrid closed loop systems will be through a 5-year phased roll out in line with NHS England's implementation plan. For enquiries about cost-effective pricing contact ...
National Institute for Health and Care Excellence

Osimertinib for adjuvant treatment of EGFR mutation-positive non-small-cell lung cancer after complete tumour resection

Guidance Standards and indicators Clinical Knowledge Summaries (CKS) British National Formulary (BNF) British National Formulary for Children (BNFC) Life sciences Library and knowledge services What ...
National Institute for Health and Care Excellence

Dostarlimab with platinum-based chemotherapy for treating advanced or recurrent endometrial cancer with high microsatellite instability or mismatch repair deficiency

Dostarlimab with platinum-based chemotherapy for treating advanced or recurrent endometrial cancer with high microsatellite instability or mismatch repair deficiency Technology appraisal guidance ...
National Institute for Health and Care Excellence

Nivolumab plus ipilimumab for untreated unresectable or metastatic colorectal cancer with high microsatellite instability or mismatch repair deficiency

There is a simple discount patient access scheme for nivolumab, and a patient access scheme plus commercial access agreement for ipilimumab. NHS organisations can get details on the Commercial Access ...
National Institute for Health and Care Excellence

Genedrive MT-RNR1 ID Kit for detecting a genetic variant to guide antibiotic use and prevent hearing loss in babies: early value assessment

We have moved Health technology evaluation 6 to become HealthTech guidance 665. This is to better reflect the NICE HealthTech programme which combines the former NICE Diagnostics Assessment programme, ...
National Institute for Health and Care Excellence

Polatuzumab vedotin with rituximab and bendamustine for treating relapsed or refractory diffuse large B-cell lymphoma

There is a simple discount patient access scheme for polatuzumab vedotin. Contact [email protected] for details. The recommendations in this guidance represent the view of NICE, arrived at ...